

ARROWHEAD PHARMACEUTICALS, INC.

Form 8-K

December 01, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 29, 2016**

**Arrowhead Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**0-21898**

**(Commission File Number)**

**Delaware**  
**(State or other jurisdiction)**

**46-0408024**  
**(IRS Employer)**

Edgar Filing: ARROWHEAD PHARMACEUTICALS, INC. - Form 8-K

of incorporation)

Identification No.)

225 South Lake Avenue, Suite 1050, Pasadena, CA 91101

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (626) 304-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 29, 2016, Arrowhead Pharmaceuticals, Inc. (the Company) notified David Lewis, the Company's Chief Scientific Officer, that his position will be terminated, effective December 13, 2016.

**Item 8.01 Other Events.**

On November 29, 2016, the Company issued a press release announcing that the Company will be discontinuing development of its clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPC<sub>iv</sub><sup>TM</sup>, or EX1, delivery vehicle and redeploying its resources to support the development of RNAi therapeutics that utilize the Company's proprietary subcutaneous and extra-hepatic delivery systems.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 1, 2016

ARROWHEAD PHARMACEUTICALS, INC.

By: /s/ Kenneth Myszkowski  
Kenneth Myszkowski  
Chief Financial Officer